Company news

CorMedix Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases

October 19, 2026

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference

September 1, 2026

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

July 29, 2026

U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation

June 7, 2026

Cormedix Therapeutics to Participate in two Upcoming Investor Conferences

May 15, 2026

Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 13, 2026

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

May 5, 2026

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

April 26, 2026

CorMedix to Participate in Needham Virtual Healthcare Conference

April 7, 2026

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 5, 2026

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

March 2, 2026

CorMedix Therapeutics Announces Share Repurchase Program

February 2, 2026

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

January 29, 2026

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 9, 2026

CorMedix Therapeutics Announces Leadership and Board Updates

January 8, 2026

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

January 7, 2026

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

December 17, 2025

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

November 11, 2025

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

November 11, 2025

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

October 30, 2025

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

October 22, 2025

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

October 19, 2025

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

September 28, 2025

CorMedix Announces Strategic Minority Investment in Talphera

September 7, 2025

Deerfield Management Announces Sale of Melinta Therapeutics

September 5, 2025

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

September 1, 2025

CorMedix to Participate in Upcoming Investor Conferences

August 27, 2025

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

August 6, 2025

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

August 6, 2025

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

June 26, 2025

CorMedix Inc. Announces Proposed Public Offering of Common Stock

June 25, 2025

CorMedix inc. Announces Customer Implementation

June 22, 2025

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

May 29, 2025

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

May 14, 2025

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

April 28, 2025

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

April 7, 2025

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 24, 2025

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

March 17, 2025

CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

January 20, 2025

CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update

January 6, 2025

CorMedix Inc. Added to Nasdaq Biotechnology Index

December 18, 2024

CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products

November 25, 2024

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

November 3, 2024

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

October 29, 2024

CorMedix Inc. Announces New Data at ASN Kidney Week 2024

October 23, 2024

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

October 22, 2024

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.